Influenza A Market Insight, Epidemiology, And Market Forecast - 2036 Now Available - See Why A 70% Vaccine Failure Rate Is Fueling The Race For Next-Gen Flu Therapies
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
A new "Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 countries comprising Germany, France, Italy, and Spain, the United Kingdom, and Japan. The study evaluates historical and forecast epidemiology, treatment practices, approved therapies, pipeline development, market access, reimbursement, competitive dynamics, and commercial opportunities from 2022 through 2036.
The United States Influenza A market was valued at approximately USD 5 billion in 2025 and is projected to approach USD 10 billion by 2036. The report estimates a compound annual growth rate of 7.9% from 2026 to 2036. Across the seven major markets, the United States represented the largest Influenza A market, while Spain recorded the smallest market size. Within Europe, Germany led the EU4 and UK market.
Influenza A Market Trends and Growth Drivers
Influenza A continues to create a substantial clinical and economic burden through seasonal epidemics and pandemic risk. During the 2025 Southern Hemisphere influenza season in the Americas, transmission exceeded the seasonal threshold by mid-March and remained at low to moderate levels, with A(H1N1)pdm09 driving most activity and peak test positivity reaching 19%.
Market growth is supported by sustained demand for vaccination, antiviral treatment, improved molecular diagnostics, and pandemic preparedness. Greater public awareness, expanded immunization initiatives, biotech investment, and international surveillance programs are also strengthening the Influenza A market outlook.
Next-generation vaccine technologies represent an important area of innovation. mRNA-based influenza vaccines under development may support faster strain adaptation and scalable manufacturing. Annual vaccination remains central to reducing severe disease, particularly among older adults, pregnant women, children, and people with underlying health conditions. For the 2025-2026 influenza season, the CDC recommended single-dose, thimerosal-free seasonal influenza vaccine formulations for children, pregnant women, and adults. On March 13, 2025, the US Food and Drug Administration issued recommendations for the composition of US influenza vaccines for the 2025-2026 season.
Influenza A Epidemiology and Patient Population
The epidemiological analysis projects an increase in Influenza A-positive cases in the United States through 2036. In 2025, vaccination coverage was highest among adults aged 18-49 years and lowest among pregnant women. The report estimates that vaccine failure affected approximately 70% of vaccinated individuals, highlighting the need for improved strain matching and more broadly protective vaccine platforms.
European surveillance indicated that A(H1N1)pdm09 was the predominant Influenza A subtype in 2024, representing approximately 57% to 93% of reported Influenza A cases. In Japan, analysis of Ministry of Health, Labour and Welfare surveillance data identified an average of approximately 196,895 weekly influenza cases in November 2025, equivalent to 51.12 cases per reporting medical institution and indicative of high epidemic intensity.
Influenza A Treatment and Diagnostic Landscape
Influenza A management is determined by disease severity, patient risk factors, and the timing of treatment. Patients at elevated risk of complications may receive antiviral therapy within 48 hours of symptom onset, while severe cases involving pneumonia, sepsis, or hospitalization require prompt treatment. Recommended antiviral options include oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil.
Diagnostic approaches include rapid influenza diagnostic tests, RT-PCR, viral culture, immunofluorescence testing, and rapid molecular assays. Improved access to sensitive molecular testing can support earlier treatment decisions, outbreak management, and more accurate surveillance.
XOFLUZA (baloxavir marboxil), developed by Roche and Shionogi, remains a prominent approved therapy. The single-dose oral antiviral inhibits cap-dependent endonuclease activity and has demonstrated activity against multiple influenza strains. In the United States, XOFLUZA is approved for acute, uncomplicated influenza in eligible patients and for post-exposure prophylaxis in specified age groups. European authorization covers uncomplicated influenza treatment and post-exposure prophylaxis in children aged one year and older, adolescents, and adults.
Influenza A Pipeline and Competitive Landscape
The Influenza A clinical pipeline includes preventive and therapeutic candidates designed to address vaccine limitations, antiviral resistance, and the continuing burden of seasonal and pandemic influenza. Prominent investigational products include MK-1406/CD388, GSK4382276A, CC-42344, and next-generation mRNA vaccine programs.
CC-42344, developed by Cocrystal Pharma, is an investigational PB2 inhibitor being evaluated as an oral treatment for pandemic and seasonal Influenza A. The candidate has shown preclinical activity against seasonal, avian, and drug-resistant Influenza A strains. The UK Medicines and Healthcare Products Regulatory Agency authorized a Phase IIa human challenge study, and Cocrystal Pharma announced plans in March 2026 to continue development through an additional Phase IIa study.
MK-1406/CD388 is being evaluated in the Phase III ANCHOR study. In January 2026, Merck announced the successful completion of a cash tender offer, through a subsidiary, to acquire the outstanding common shares of Cidara Therapeutics. In February 2026, the Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Moderna's mCombriax influenza vaccine.
Other notable developments include publication of a detailed Phase III CENTERSTONE analysis of XOFLUZA in the New England Journal of Medicine in April 2025. The study evaluated the therapy's potential to reduce influenza virus transmission.
Unmet Needs and Influenza A Market Opportunities
Major unmet needs include variable vaccine effectiveness, antiviral resistance, limited treatment innovation, production constraints, uneven vaccination uptake, and the economic burden associated with seasonal outbreaks. Antigenic drift and shift continue to affect vaccine performance and complicate long-term prevention strategies.
Commercial opportunities are expected to emerge from universal and mRNA vaccine platforms, novel antiviral mechanisms, long-acting preventive therapies, modernized manufacturing, and more accurate diagnostics. Behavioral interventions, including vaccination adherence and infection-control practices, will remain important for protecting high-risk populations.
Market access and reimbursement will significantly influence the adoption of emerging Influenza A therapies. The report assesses country-specific reimbursement conditions, treatment costs, analogue pricing, cost-effectiveness, government prescription programs, patient out-of-pocket expenses, and alternative payment models. Pricing strategies aligned with measurable clinical benefit will be critical to securing payer coverage and supporting long-term uptake.
Influenza A Market Report Coverage
The report combines epidemiology-based bottom-up forecasting with primary and secondary research. More than 15 key opinion leaders and subject matter experts were consulted across major markets, including specialists affiliated with leading academic and medical institutions in the United States, United Kingdom, Germany, and other countries.
Coverage includes:
- Influenza A patient population and epidemiology forecasts United States, European, UK, and Japan market analysis Historical and projected market size from 2022 to 2036 Approved therapy and emerging drug profiles Clinical development, regulatory, patent, and partnership analysis Therapy adoption, drug uptake, and peak patient-share forecasts Influenza A pricing, reimbursement, and market access trends Competitive intelligence and major company strategies SWOT and conjoint analysis of current and emerging therapies Unmet needs, treatment algorithms, and commercial opportunities
A selection of companies mentioned in this report includes, but is not limited to:
- Roche BioCryst Pharmaceuticals Seqirus Moderna Merck (Cidara Therapeutics) GlaxoSmithKline Cocrystal Pharma
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment